In the highly competitive and regulated world of pharmaceutical testing, where precision, speed, and regulatory compliance are key to success, one company has emerged as a trusted ally for pharmaceutical manufacturers, compounding pharmacies, and healthcare providers alike. Founded in 2011 by Lisa McChesney-Harris, PhD, Prompt Praxis Laboratories (PPL) has built a stellar reputation by delivering high-quality analytical testing services tailored to meet the needs of the pharmaceutical, veterinary, and wellness industries. What sets the company apart from others in the analytical testing space is its unique blend of technological innovation, scientific rigor, and a commitment to customer service. Headquartered in Vernon Hills, IL, Prompt Praxis Laboratories was conceived out of Lisa McChesneyHarris’s frustration with the inefficiencies she encountered working with third-party laboratories. Time and again, she noticed recurring problems—sluggish turnaround times, inconsistent data quality, a lack of transparency, and ever-escalating project costs. These challenges were not just operational but also had a direct impact on the regulatory compliance and market readiness of pharmaceutical products. “I knew the industry needed something better,” McChesney-Harris explains. “We saw an opportunity to build a laboratory from the ground up that would eliminate these common pitfalls. It had to be fast, reliable, transparent, and focused on regulatory excellence.” A Vision for Excellence in Pharmaceutical Testing PPL’s approach has always been centered on innovation, efficiency, and operational excellence. From its inception, the company set out to solve the issues that plagued traditional laboratories, especially in the fast-paced and ever-changing pharmaceutical sector. Unlike many labs that rely on paper-based documentation, PPL adopted the NuGenesis Laboratory Management System (LMS) early on, which allowed them to shift to a completely digital and integrated workflow. This move not only improved efficiency but also enabled real-time data capture and seamless integration of testing processes, resulting in faster turnaround times and a higher level of compliance with regulatory standards. The adoption of digital infrastructure was only the beginning of PPL’s journey. The company also implemented ultra-performance liquid chromatography (UPLC) and Waters' Empower software, two key components that allow them to achieve precise and rapid analytical testing across a broad range of compounds. With these tools, PPL ensures that all tests, whether for compounded sterile preparations (CSPs), generic injectables, or veterinary products, meet the highest standards of accuracy and reliability. “We knew from the start that technology would be a key differentiator,” says McChesney-Harris. “But technology alone isn’t enough. We had to create a culture of excellence where every member of the team was aligned with our mission to provide top-tier service, no excuses.”

Modified mRNA has revolutionized modern medicine by vaccines, gene replacing therapies and accelerating healing. Traditionally, it is injected directly into tissue or the bloodstream to trigger profound cellular changes and deep recovery. However, what if that same power could be delivered without a needle or any specialized procedure? BEMY Cosmetics is turning that possibility into reality by translating patented modified mRNA-based process into everyday personal skincare products. The company adopts a radically different strategy from therapeutic medicine. Instead of injecting RNA as an active agent, it uses modified mRNA to instruct skin cells ex-vivo to synthesize valuable growth factors. Once produced, those factors are harvested in a cell culture fluid known as conditioned medium. This bioactive solution, qualified by FDA as natural and serves as the heart of BEMY’s personalized skincare line. No injections. No artificial compounds. Just a topical cream that communicates directly with living skin and awakens its innate ability to repair, regenerate, and refresh itself over time. “Our story is more than skincare; it is about beauty powered by one’s own biology,” explains Brad Pylant, co-founder and CEO of BEMY Cosmetics. “By guiding skin cells ex-vivo to produce growth factor-enriched medium, our proprietary modified mRNA-based process offers a genuinely groundbreaking treatment that redefines what skincare can achieve.”.

Mountaineer Biosciences is a boutique scientific consulting firm guiding innovation in inflammation and immunology. It provides end-to-end support for biopharma and biotech companies to advance therapies from discovery to commercialization. The firm works at the intersection of science and strategy, shaping research and development plans, aligning with regulatory and investor expectations, and enabling smooth progression through each phase. Throughout their careers, the team has supported more than nine approved therapies, including OPZELURA^®, JAKAFI^®, SPEVIGO^®, SKYRIZI^®, TEZSPIRE^®, and ADBRY^®. “We personally invest in each client relationship, committed to building partnerships that last,” says Michael D. Howell, founder and president. Mountaineer Biosciences is led by Michael Howell, PhD, and Ashley R. Murray-Howell, PhD, who bring decades of scientific and translational expertise across the drug development lifecycle. Dr. Howell brings deep expertise in immune system modulation, helping clients determine which disease mechanisms to pursue based on their therapeutic approach. Dr. Murray-Howell applies her background in pharmacology, physiology and metabolic science to lead translational planning, scientific due diligence and program evaluation. Together, they provide the strategic and scientific leadership typically delivered by the Chief Scientific Officer and Chief Development Officer. Built to Fill a Critical Gap in Scientific Leadership Mountaineer Biosciences was founded during the COVID-19 pandemic, a time when many pharmaceutical R&D divisions were downsized or restructured to focus on vaccines and high-priority public health needs. Inflammation and immunology programs, particularly those in early or translational stages, were left with limited access to scientific leadership. At the time, Michael had already earned a reputation as a respected advisor across industry and academia. A former faculty member at National Jewish Health, he played a central role in interrogating the mechanisms underlying atopic dermatitis and asthma—contributions that laid the groundwork for multiple now-approved therapies. Growing demand for his guidance led to the formal creation of Mountaineer Biosciences..

Clinical trials often rely on brief clinic visits and isolated tests, which miss the full picture of daily living patterns. These snapshots can obscure important changes in mobility, sleep, cognition, medication adherence, and social engagement. Sponsors face significant costs and lengthy timelines because large, multisite samples are required to detect subtle shifts. Participants from rural areas, assisted living facilities, or low-income communities frequently encounter enrollment and retention challenges. Data collected in this fragmented and delayed manner limits causal insights and slows decision-making. Remote, continuous monitoring offers richer, real-world metrics and stronger statistical power. Achieving meaningful results depends on datasets that include outcomes validated against pathology-confirmed measures, a feature rarely found in digital health research. To address these challenges, Life Analytics delivers this capability through its Life Analytics Monitoring Platform (LAMP), designed to enhance trial design, data capture, and analysis. The platform’s adaptability enables its use across any trial type, whether involving healthy volunteers in early-phase studies or participants managing chronic or neurodegenerative conditions. Its device-agnostic design supports a wide range of sensors, making it equally effective for drug discovery, chronic disease research, and wellness-focused studies. Through this approach, the platform captures a continuous, real-world picture of health and behavior across domains that matter, including mobility, cognition, sleep, socialization, physiology, and safety. It derives insights from data collected unobtrusively through connected devices, revealing whether someone is functioning better in their everyday environment. “Our platform is HIPAA-compliant and offers a preselected set of biomarkers that capture critical patient information in real time while securely transferring this data to servers for ongoing monitoring of the patient’s condition,” says Larry Frye, CEO. Patients are more likely to remember to take medications, sleep consistently, use devices effectively, and maintain better engagement. These changes are tracked using real-time biomarkers. This level of observation provides greater statistical power and allows researchers to detect changes with fewer patients. As a result, trials can progress more quickly while minimizing exposure to potential side effects..